Go back to Healthcare Systems
Appetite for Change: The Obesity Epidemic Meets Biotech
Cambridge Associates
Obesity is a global health crisis. With over 650 million adults affected worldwide, it drives massive economic and disease burdens. Yet new treatment options like an oral GLP-1 drug can offer hope.
Episode four of Unseen Upside: Investments Beyond Their Returns analyzes the investment landscape and future of obesity therapeutics, focusing on transformational GLP-1 drugs like Ozempic that curb appetite. Join us as we investigate the promise and challenges of emerging anti-obesity drugs, learn about one patient’s journey taking them, and discover what the future of weight loss medicine could look like.
We’ll hear from leaders in this space as well as one patient. Guests includ:
- Rod Wong, Founder, Managing Partner, and Chief Investment Officer at RTW Investments
- Raymond Stevens, Ph.D., Chief Executive Officer at Structure Therapeutics
- Dean Dimizas, Partner and Managing Director at Cambridge Associates
- Kathleen Mikaelian, Patient
Listen below or wherever you get your podcasts.
